IKOULA: Gauvain Report & Cloud Act : The Importance of Choosing a European Cloud Provider
Following the entry into force of the Cloud Act, some concerns about data sovereignty have been – and still are – heard. But consequences of this law are still too often downplayed.
On June 26th, the French Member of Parliament Raphaël Gauvain presented to the Prime Minister a report entitled “ Restoring the France & Europe sovereignty, and protecting our companies from laws and measures with extraterritorial scope ”, which clearly sets outs the risks incurred by companies using US Cloud providers : “Today, companies do not have the legal tools to effectively defend themselves against extraterritorial legal actions, lead by competitors or by foreign authorities […]. ”
Another alarming fact : « […] the prosecutions coming from Cloud Act appear to be economically motivated and the targets appear to be chosen on purpose. Important American companies are mostly spared from prosecution, and only large European and Asian companies - which compete directly with American companies – are targeted.”
On other words, as well as targeting a very wide range of offenses (the so-called “serious crime”), Cloud Act exposes European companies to a double risk:
a financial risk:
as Cloud Act is incompatible with the GDPR, companies are liable to a fine of 4% of their turnover in case of use of personal data.
- a loss of know-how risk for companies , everything without even being informed.
At IKOULA, ensuring total data sovereignty for our customers is extremely important and essential.
We will never repeat this enough, to protect their data and to guard against interference, it is vital for companies to opt for European service providers which have no ties with American laws.
Pioneer of the French Cloud since 1998, IKOULA owns its own Datacenters in France (Reims and Laon), as well as two subsidiaries in Spain and the Netherlands. Because Human Being is part of its DNA, IKOULA maintains a close relationship with its customers, and puts at their disposal reactive teams of experts, available 24/7, able to advise them and accompany them in their activities. IKOULA's teams are multilingual, in order to meet the internationalization challenges of all its customers, spread over more than 60 countries on 4 continents.
Laurane VASSOR ARCARO – +33 01 84 01 02 69
Céline BERNARD - +33 06.10.78.41.73
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Declares Dividend for Fourth Quarter 201912.12.2019 00:15:00 EET | Press release
Regulatory News: IFF (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF), a leading innovator of taste, scent and nutrition announced that its Board of Directors has declared a regular quarterly cash dividend of $0.75 per share of its common stock, payable on January 7, 2020 to shareholders of record as of December 27, 2019. Welcome to IFF At IFF (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com, Twitter , Facebook, Instagram, and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20191211005907/en/ Contact information Michael DeVeau Head of Investor Relations and Communications & Divisional CFO, Scent 212.708.7164 Michael.DeVeau@iff.com
Kite Submits Biologics License Application to U.S. Food and Drug Administration for Company’s Second CAR T Cell Therapy12.12.2019 00:05:00 EET | Press release
Kite, a Gilead Company (Nasdaq: GILD), today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the investigational chimeric antigen receptor (CAR) T cell therapy, KTE-X19, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). The BLA submission is based on data from the Phase 2 ZUMA-2 trial, which demonstrated an overall response rate of 93 percent, including 67 percent with complete response, as assessed by an Independent Radiologic Review Committee (IRRC) following a single infusion of KTE-X19. In the safety analysis, Grade 3 or higher cytokine release syndrome (CRS) and neurologic events were seen in 15 percent and 31 percent of patients, respectively. No Grade 5 CRS or neurologic events occurred. Detailed findings from this trial were recently presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando. “There remains a significant need
PTW International Announces Orange Rock Studios, Their Product and Game Development Arm11.12.2019 20:00:00 EET | Press release
Pole to Win International, Ltd. (PTW), the industry-leading video games and tech services outsourcer, today announced the launch of its product and game development arm, Orange Rock Studios. Orange Rock Studios will enhance the service offering of PTW, a gaming industry stalwart with an established and diverse dossier of top-tier clients across multiple verticals. “The time to be disruptive is now,” said Deborah Kirkham, CEO of PTW. “At Orange Rock, we foster future technologies to anchor projects with ingenuity and discipline for generation Y and Z. Together with our clients, we envision and engineer digital experiences.” “Orange Rock is the engine that will build PTW’s future by enabling us to bring each of our existing service lines - Quality Assurance, Customer Support, Audio Production, Localization, and Translation - to the forefront of their fields through cutting edge in-house tool development. We will deliver the creative products that accelerate our industry’s progress toward
Fastly Shares the Most Notable Internet Infrastructure Milestones of 2019, and What 2020 Might Bring for the Expansion of Platform-Independent Computing11.12.2019 19:30:00 EET | Press release
Fastly, Inc. (NYSE: FSLY), provider of a global edge cloud platform, today released its “Behind the Screens” retrospective detailing 2019’s notable milestones in internet infrastructure, from the increased adoption of modernized protocols, to the growth in reach and capacity of global high-speed internet, and more. Fastly’s CTO and co-founder, Tyler McMullen, anticipates that these advancements, combined with the rise of WebAssembly and the extension of code portability across platforms and devices, set the programming world up for achieving broader value from serverless computing. The State of Internet Infrastructure in 2019 This year saw a groundswell of grassroots protocol improvements, sweeping shifts toward encryption due to increased focus on data privacy, and a preview into WebAssembly’s possibilities at the edge, as well as: New satellites that took to the sky and submarine cables that were installed to grow capacity around the globe. Congestion control reimagined through BBR,
Invicro Supports the Alzheimer’s Disease Neuroimaging Initiative11.12.2019 18:37:00 EET | Press release
Invicro LLC, a Konica Minolta Company, today announced funding support for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and two of their distinguished scientists within the Alzheimer’s biomarkers space, Drs. Roger Gunn and Kenneth Marek, will join the ADNI-Private Partner Scientific Board (PPSB). Invicro is a global provider of imaging biomarkers, core lab services, advanced analytics and software solutions for drug discovery and development. ADNI is a longitudinal multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer’s disease (AD). ADNI’s mission strives to detect AD at the earliest stage possible (pre-dementia) and identify ways to track the disease’s progression with biomarkers, as well as support advances in AD intervention, prevention, and treatment. “Invicro is delighted to support ADNI which plays a central role in the development of biomarkers that enable advances in AD interven
Sevan Elevate Brings Safety and Sustainability to New Heights11.12.2019 17:00:00 EET | Press release
Sevan Multi-Site Solutions, Inc. (Sevan), a global leader in data analytics, surveys, design, program management and construction services, is excited to announce the launch of Sevan Elevate, a program that will reinforce and continuously improve Safety and Sustainability across the company to deliver excellence to people and clients. Safety and Sustainability have been a strategic imperative since 2011 when Sevan was founded by a handful of entrepreneurs, including President and CEO Jim Evans. “Sevan’s tenets are Safety and Sustainability—both of which are woven through every element of the company. It is imperative that all our people—including team members, clients and business partners—return home safely to their loved ones at the end of the day,” Evans said. “With Sevan Elevate, the company is more committed than ever to raise awareness and compliance of Safety and Sustainability throughout the multi-site construction world. We’re not going to change the world overnight, but we ca
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom